Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension
- PMID: 34491661
- DOI: 10.1056/NEJMoa2111437
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension
Abstract
Background: The appropriate target for systolic blood pressure to reduce cardiovascular risk in older patients with hypertension remains unclear.
Methods: In this multicenter, randomized, controlled trial, we assigned Chinese patients 60 to 80 years of age with hypertension to a systolic blood-pressure target of 110 to less than 130 mm Hg (intensive treatment) or a target of 130 to less than 150 mm Hg (standard treatment). The primary outcome was a composite of stroke, acute coronary syndrome (acute myocardial infarction and hospitalization for unstable angina), acute decompensated heart failure, coronary revascularization, atrial fibrillation, or death from cardiovascular causes.
Results: Of the 9624 patients screened for eligibility, 8511 were enrolled in the trial; 4243 were randomly assigned to the intensive-treatment group and 4268 to the standard-treatment group. At 1 year of follow-up, the mean systolic blood pressure was 127.5 mm Hg in the intensive-treatment group and 135.3 mm Hg in the standard-treatment group. During a median follow-up period of 3.34 years, primary-outcome events occurred in 147 patients (3.5%) in the intensive-treatment group, as compared with 196 patients (4.6%) in the standard-treatment group (hazard ratio, 0.74; 95% confidence interval [CI], 0.60 to 0.92; P = 0.007). The results for most of the individual components of the primary outcome also favored intensive treatment: the hazard ratio for stroke was 0.67 (95% CI, 0.47 to 0.97), acute coronary syndrome 0.67 (95% CI, 0.47 to 0.94), acute decompensated heart failure 0.27 (95% CI, 0.08 to 0.98), coronary revascularization 0.69 (95% CI, 0.40 to 1.18), atrial fibrillation 0.96 (95% CI, 0.55 to 1.68), and death from cardiovascular causes 0.72 (95% CI, 0.39 to 1.32). The results for safety and renal outcomes did not differ significantly between the two groups, except for the incidence of hypotension, which was higher in the intensive-treatment group.
Conclusions: In older patients with hypertension, intensive treatment with a systolic blood-pressure target of 110 to less than 130 mm Hg resulted in a lower incidence of cardiovascular events than standard treatment with a target of 130 to less than 150 mm Hg. (Funded by the Chinese Academy of Medical Sciences and others; STEP ClinicalTrials.gov number, NCT03015311.).
Copyright © 2021 Massachusetts Medical Society.
Comment in
-
Moving the Goalposts for Blood Pressure - Time to Act.N Engl J Med. 2021 Sep 30;385(14):1328-1329. doi: 10.1056/NEJMe2112992. Epub 2021 Aug 30. N Engl J Med. 2021. PMID: 34491660 No abstract available.
-
Intensive blood pressure control benefits older patients.Nat Rev Cardiol. 2021 Nov;18(11):739. doi: 10.1038/s41569-021-00626-0. Nat Rev Cardiol. 2021. PMID: 34526678 No abstract available.
-
Another STEP towards tighter control of blood pressure in the elderly.Eur Heart J. 2021 Dec 7;42(46):4715-4716. doi: 10.1093/eurheartj/ehab728. Eur Heart J. 2021. PMID: 34875057 No abstract available.
-
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.N Engl J Med. 2021 Dec 30;385(27):2588-2589. doi: 10.1056/NEJMc2117463. N Engl J Med. 2021. PMID: 34965350 No abstract available.
-
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.N Engl J Med. 2021 Dec 30;385(27):2589. doi: 10.1056/NEJMc2117463. N Engl J Med. 2021. PMID: 34965351 No abstract available.
-
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.N Engl J Med. 2021 Dec 30;385(27):2589-2590. doi: 10.1056/NEJMc2117463. N Engl J Med. 2021. PMID: 34965352 No abstract available.
-
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension.N Engl J Med. 2021 Dec 30;385(27):2590. doi: 10.1056/NEJMc2117463. N Engl J Med. 2021. PMID: 34965353 No abstract available.
Similar articles
-
Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.N Engl J Med. 2021 May 20;384(20):1921-1930. doi: 10.1056/NEJMoa1901281. N Engl J Med. 2021. PMID: 34010531 Free PMC article. Clinical Trial.
-
Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial.JAMA. 2016 Jun 28;315(24):2673-82. doi: 10.1001/jama.2016.7050. JAMA. 2016. PMID: 27195814 Free PMC article. Clinical Trial.
-
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9. N Engl J Med. 2015. PMID: 26551272 Free PMC article. Clinical Trial.
-
Effects of intensive blood pressure treatment on orthostatic hypertension: individual level meta-analysis.BMJ. 2025 Mar 25;388:e080507. doi: 10.1136/bmj-2024-080507. BMJ. 2025. PMID: 40132860 Free PMC article.
-
Effect of intensive versus standard blood pressure control on cardiovascular outcomes in adult patients with hypertension: a systematic review and meta-analysis.Hypertens Res. 2025 Jun;48(6):1846-1858. doi: 10.1038/s41440-025-02131-0. Epub 2025 Feb 13. Hypertens Res. 2025. PMID: 39948181
Cited by
-
The first software as medical device of evidence-based hypertension digital therapeutics for clinical practice.Hypertens Res. 2022 Dec;45(12):1899-1905. doi: 10.1038/s41440-022-01016-w. Epub 2022 Oct 7. Hypertens Res. 2022. PMID: 36207530 Free PMC article. Review.
-
Medical Telemonitoring for the Management of Hypertension in Older Patients in Japan.Int J Environ Res Public Health. 2023 Jan 26;20(3):2227. doi: 10.3390/ijerph20032227. Int J Environ Res Public Health. 2023. PMID: 36767594 Free PMC article. Review.
-
Management of Diabetes and Hypertension within the Gulf Region: Updates on Treatment Practices and Therapies.Diabetes Ther. 2022 Jul;13(7):1253-1280. doi: 10.1007/s13300-022-01282-4. Epub 2022 Jun 9. Diabetes Ther. 2022. PMID: 35679010 Free PMC article. Review.
-
Landscape of cardiometabolic risk factors in Chinese population: a narrative review.Cardiovasc Diabetol. 2022 Jun 21;21(1):113. doi: 10.1186/s12933-022-01551-3. Cardiovasc Diabetol. 2022. PMID: 35729555 Free PMC article. Review.
-
The Pivotal Role of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertension Management and Cardiovascular and Renal Protection: A Critical Appraisal and Comparison of International Guidelines.Am J Cardiovasc Drugs. 2023 Nov;23(6):663-682. doi: 10.1007/s40256-023-00605-5. Epub 2023 Sep 5. Am J Cardiovasc Drugs. 2023. PMID: 37668854 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical